AndreaBozzo/ceres-open-data-index huggingface dataset:
Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System

<p>The Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system is an extensible, scalable informatics platform for TBI relevant imaging, assessment, genomics, and other data types. It was developed to share data across the entire TBI research field and to facilitate collaboration between laboratories, as well as interconnectivity with other informatics platforms.</p>
Patent AT-E399889-T1: [Translated] METHOD AND DEVICE FOR COATING A SUBSTRATE

The invention relates to a method for coating a substrate with a layer of a material, such as a metal, in which a quantity of electrically conductive material is vaporized in a space with a low background pressure and energy is supplied to the material which is to be vaporized in order to vaporize this material. According to the invention, the material which is to be vaporized, while it is being vaporized, is kept floating, without support, in the space and is enclosed in an alternating electromagnetic field, the alternating electromagnetic field being generated with the aid of a high-frequency alternating current. The invention also relates to a device for coating a substrate and to a substrate.
Compound 528017: Ethanol, 2,2,2-trichloro, 4-nitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl 4-nitrobenzoate. Molecular Formula: C9H6Cl3NO4. Molecular Weight: 298.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Cryptosporidiosis to Dengue

NNDSS - Table II. Cryptosporidiosis to Dengue - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.    NP: Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Data for dengue-like illness will be included in this table after the CDC obtains Office of Management and Budget (OMB) Paperwork Reduction Act (PRA) to receive data for this condition.
Patent AT-E400221-T1: [Translated] SURGICAL CLAP SETTING DEVICE WITH A SINGLE LOCKING MECHANISM

A surgical instrument includes an E-beam firing bar engages the channel and selectively engages the anvil during distal firing movements, wherein the tissue is severed and stapled driven upward from the staple cartridge to form against the anvil. In particular, a wedge integral to the staple cartridge is driven distally by a middle pin of the firing bar to effect stapling. A single lockout of the staple channel responds to the presence of the wedge sled in its unfired position to allow the firing bar to fire. Otherwise, the single lockout prevents firing when the staple cartridge is missing or spent. Further, some versions include an Electroactive Polymer (EAP) actuator that presents an abutting surface, or acts as a trapdoor to a ramped recess in a staple channel to block the firing bar, as an active approach to preventing firing for one or more conditions.
Using Qualitative Data in Program Evaluation: Telling the Story of a Prevention Program

This webinar explores the value of qualitative methods, which include a number of data collection strategies suitable for many purposes: ethnography, cognitive psychology, case study, action research, oral history, and policy research. In qualitative inquiry, every story's important, and every voice is an important version of the truth; it gives a voice to people who often go unheard.

Presenters: Cassandra Firman, Training and Technical Assistance Coordinator, FRIENDS; Susan Janko Summers, author and consultant to FRIENDS

View Webinar (WMV - 76 MB)

Metadata-only record linking to the original dataset. Open original dataset below.
Contact After Adoption or Guardianship: Child Welfare Agency and Family Interactions

The purpose of the Understanding Post Adoption and Guardianship Instability for Children and Youth Who Exit Foster Care project is to examine rates of instability, factors associated with instability, and the supports and resources that promote post-permanency stability. Ultimately, the project aims to support efforts to build the capacity of federal, state, and local agencies to get accurate information about instability for children who exit foster care to adoption or guardianship. In order to examine these issues, two separate studies were conducted 1.) The Contact After Adoption or Guardianship: Child Welfare Agency and Family Interactions Study and 2.) The Survey of National Survey of Child and Adolescent Well-Being (NSCAW) Adopted Youth, Young Adults, Adults, and Adoptive Parents.  This dataset contains data from The Contact After Adoption or Guardianship: Child Welfare Agency and Family Interactions Study.

The Contact After Adoption or Guardianship: Child Welfare Agency and Family Interactions Study (hereafter referred to as “The Contact After Adoption or Guardianship Study”) seeks to understand child welfare agency processes and procedures to help obtain better information on post adoption and post guardianship instability. The study explores the intentional and unintentional ways public child welfare agencies contact or receive information about the well-being of children and youth (and in particular, their experiences of instability) who have exited the foster care system through adoption or guardianship. Additionally, this study investigates how child welfare agencies track children and youth who exit the foster care system to adoption or guardianship and what information they collect.  The study used two web-based surveys of adoption program managers (APMs) in all 50-states. One web survey focused on adoption practices, which all AMPs received, and one focused on guardianship practices. Only APMs from the 38 states that have a federally subsidized guardianship program (i.e., Kin-GAP) were asked to complete the separate guardianship survey.  Seventy-two percent of the 50 APMs responded to the adoption survey and 63% of the 38 guardianship APMs responded to the guardianship survey.

Investigators: Nancy Rolock, PhD
Case Western Reserve University Cleveland, OH
Kevin White, PhD.
East Carolina University Greenville, NC
Heather Ringeisen, PhD
RTI International Research Triangle Park, NC
Rose Domanico, MA
RTI International Research Triangle Park, NC
Rong Bai, PhD
Case Western Reserve University Cleveland, OH

Leyla Stambaugh, PhD
RTI International Research Triangle Park, NC
Patent AT-E401602-T1: [Translated] METHOD AND APPARATUS FOR USE IN DECODING EXECUTE CODE

The invention provides for a method and related device and control program for use in decoding executable code in a processing system, for example run-time operating system, including bit-shuffling code at run-time, and including the steps of dividing the code into a plurality of sub-portions, identifying sub-portions of the code that can be bit-shuffled prior to the said run-time and bit-shuffling the said identified sub-portions prior to run-time so as to reduce the bit-shuffling required at run-time.
Agile Readiness A Conversation with Leading Agile Coaches

The Children’s Bureau (CB) is currently providing technical assistance and coaching to states interested in leveraging an Agile framework into their procurement, development, and management approach to child welfare development projects. LeadingAgile is the agency contracted with CB to provide this short term technical assistance to states who have interest in utilizing Agile methodologies.

In this presentation LeadingAgile staff provided an overview of the services provided to various states over the past few months. They shared the common strengths and challenges that they came across during these various visits. They also shared the five key success factors which can help states implement successful Agile project management methodologies.

Our speakers were:

Metadata-only record linking to the original dataset. Open original dataset below.
V-safe RSV for Pregnant Women

Users of the V-safe data are required to adhere to the following standards for the analysis and reporting of research data. All research results must be presented and/or published in a manner that protects the confidentiality of participants. V-safe data will not be presented and/or published in any way in which an individual can be identified. Therefore, users will:
<ol>
<li>Not attempt to link or permit others to link the data with individually identified records in another database.</li>
<li>Not attempt to learn the identity of any participant in the data and will not deliberately combine these data with other CDC or non-CDC data for the purpose of matching records to identify individuals. If you should inadvertently discover the identity of any participant, you will ensure the identity of any participant is kept confidential, and will not be used in any publications and/or presentations.</li>
<li>Not imply or state, either in written or oral form, that interpretations based on analysis of the data reflect official CDC policies or positions.</li>
<li>Understand that sub-national analyses are not appropriate for this national sample and will not be conducted. </li>
<li>Understand that V-safe is a voluntary self-enrollment program requiring smartphone access; therefore, information from V-safe might not be representative or generalizable to the US population.</li></ol>
By clicking on the weblink below to download and use these V-safe data, you signify your agreement to comply with the above-stated terms.

V-safe is a voluntary U.S. active safety surveillance system established by CDC to characterize local and systemic side effects of new vaccines administered after U.S. authorization or licensure. V-safe participants are not a random sample of all vaccinated persons in the United States and data might not be generalizable to the full U.S. vaccinated population. Participants may have been more likely to complete surveys if experiencing symptoms post-vaccination. All V-safe measures are self-reported, therefore there may be some misclassification of outcomes, vaccine-related information, or demographics.

Mobile outages or technical malfunctions may have caused a small number of missing surveys or collection of incorrect survey type. Occasional system outages and attrition over time also contribute to incomplete reporting. 

V-safe RSV for Pregnant Women public data includes enrollment, vaccination information, and daily and weekly surveys collected from 11/28/2023 to 3/23/2025. Corresponding V-safe Registration public data (de-identified demographic data) can be downloaded at data.cdc.gov. Please review the V-safe data user agreement before analyzing any V-safe data.
Compound 529822: Propanal, 2,4,6-trichlorophenyl hydrazone, #1

Chemical compound data from PubChem database. IUPAC Name: 2,4,6-trichloro-N-(propylideneamino)aniline. Molecular Formula: C9H9Cl3N2. Molecular Weight: 251.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528486: Eicosane, 2,6,10,15-tetramethyl

Chemical compound data from PubChem database. IUPAC Name: 2,6,10,15-tetramethylicosane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2014 CMHS Uniform Reporting System (URS) Table for Alaska

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Alaska. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 525139: Butyl octyl terephthalate

Chemical compound data from PubChem database. IUPAC Name: 1-O-butyl 4-O-octyl benzene-1,4-dicarboxylate. Molecular Formula: C20H30O4. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 CMHS Uniform Reporting System (URS) Output Table for Ohio

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528637: 2,3-Pentanediol, di-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl(2-trimethylsilyloxyhexan-3-yloxy)silane. Molecular Formula: C12H30O2Si2. Molecular Weight: 262.54. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529030: Oxazole, 4,5-diethyl

Chemical compound data from PubChem database. IUPAC Name: 4,5-diethyl-1,3-oxazole. Molecular Formula: C7H11NO. Molecular Weight: 125.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Care Individual Provider Network Data: June 30, 2014

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects individual provider data. Provider Network Data System information is self-reported. For more information, check out http://www.health.ny.gov/health_care/managed_care/.
Compound 528703: 2-Cyclopenten-1-one, 2-hydroxy-3-ethyl-5-methyl

Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-2-hydroxy-5-methylcyclopent-2-en-1-one. Molecular Formula: C8H12O2. Molecular Weight: 140.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527292: Propanoic acid, 2-methyl, 2-bromoethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2-bromoethyl 2-methylpropanoate. Molecular Formula: C6H11BrO2. Molecular Weight: 195.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Systemic toxicity induced by topical application of heptafluorobutyric acid (PFBA) in a murine model

Heptafluorobutyric acid (PFBA) is a synthetic chemical belonging to the per- and polyfluoroalkyl substances (PFAS) group that includes over 5,000 chemicals.  PFBA is a short-chain PFAS (C4) that has been labeled as a safer alternative to the legacy PFAS perfluorooctanoic acid (PFOA) and perfluorooctane sulfate (PFOS) which have been linked to numerous health effects.  This class of chemicals are incorporated into consumer products such as stain resistant carpeting and textiles, nanosprays, medical devices, and fire-fighting foams.  There is a high potential for occupational exposure and in the environment, PFBA has been detected in a variety of water sources leading to concerns for dermal exposure, however, these studies are lacking.  In previous studies from our lab, PFOA was demonstrated to be absorbed via the skin and immunomodulatory.  In the present study, the systemic toxicity of a 28-day dermal PFBA (3.75-15% w/v, or 93.8-375 mg/kg/dose) exposure was evaluated in a murine model.
Patent AT-E400336-T1: [Translated] ARRANGEMENT FOR MOUNTING A SKI BINDING, A SKI BINDING PART OR ONE OF THESE OR THIS SUPPORTING PART, PARTICULARLY PLATE-SHAPED, ON A SKI

A ski boot is coupled to a ski by a ski binding with a base plate (1) which engages with the ski top surface. The base plate has a castellated profiled lower surface that engages in a corresponding profile in the ski upper surface.
National Directory of Drug and Alcohol Abuse Treatment Facilities - 1979

The National Directory of Drug and Alcohol Abuse Treatment Programs 1979 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1978 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1978 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Patent AT-E400064-T1: [Translated] RESISTIVE TYPE CURRENT LIMITING DEVICE HAVING A HIGH-TC TAPE SUPERCONDUCTOR

A strip-shaped superconductor has a conductor structure containing at least one metallic substrate strip, a layer made of oxidic high T<SUB>c </SUB>superconducting material of the AB<SUB>2</SUB>Cu<SUB>3</SUB>OX type; an oxidic buffer layer, which is arranged therebetween and which has adapted crystalline dimensions, and; a normal-conductive top layer that is applied to the superconductive layer. The buffer layer should be formed so that a transition resistance of no greater than 10<SUP>-3 </SUP>Omegacm<SUP>2 </SUP>is formed at least in partial areas between the superconductive layer and the substrate strip. For example, suitable materials are of the La-Mn-O or Sr-Ru-O or La-Ni-O or In-Sn-O type.
Hospital Inpatient Discharges (SPARCS De-Identified): Pediatric Prevention Quality Indicators (PDI) by Patient County: Beginning 2009

The dataset contains observed, expected, and risk-adjusted rates for the Agency for Healthcare Research and Quality Pediatric Quality Indicators – Pediatric (AHRQ PDI) beginning in 2009.
The AHRQ PDIs are a set of population based measures that can be used with hospital inpatient discharge data to identify ambulatory care sensitive conditions. These are conditions where 1) the need for hospitalization is potentially preventable with appropriate outpatient care, or 2) conditions that could be less severe if treated early and appropriately. Both the Urinary Tract Infection and Gastroenteritis PDIs include admissions for patients aged 3 months through 17 years.  The asthma PDI includes admissions for patients aged 2 through 17 years.  Eligible admissions for the Diabetes Short-term Complications PDI includes admissions for patients aged 6 through 17 years.

The rates were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data and Claritas population information.  

The observed, expected, risk-adjusted rates, and difference in rates, for each AHRQ PDI are presented by resident county (including a statewide total).
Managed Care Plan Utilization Data: Beginning 2009

The New York State Department of Health (NYSDOH) collects annual data on children’s and adults’ use of health services. This information complements the quality of care and member satisfaction information collected through an annual public reporting system called the Quality Assurance Reporting Requirements (QARR).  Utilization measures are designed to capture the frequency of certain services provided by health plans. NCQA does not view higher or lower services counts as better or worse performance. Plans with fewer than 30 eligible events are excluded from the statistical calculations of the percentiles.
Reactivation of a silenced

Background
          The active copy of the imprinted gene H19 is turned off by inappropriate methylation in several pediatric tumors including Wilms' Tumour and embryonal rhabdomyosarcoma. H19 controls in cis the linked Insulin-like Growth Factor 2 (IGF2) gene, encoding an important growth factor. Recent work has suggested that methylation of a gene may lead to deacetylation of its associated histones and that silenced genes can be reactivated by increasing histone acetylation levels.
        
        
          Results
          Treatment of a rhabdomyosarcoma cell line which has a silent, methylated H19 gene with histone deacetylase (HDAC) inhibitors under conditions which gave maximal hyperacetylation of histone 4, both globally and at the H19 gene itself could not reactivate H19 or affect the active Insulin-like Growth Factor 2 (IGF2) gene, but caused clear up-regulation of the Tissue-type Plasminogen Activator (TPA) gene, a non-imprinted gene known to respond to changes in histone acetylation. In contrast, mild treatment of the cells with the methylation inhibitor 5-AzaC-2'-deoxycytidine (AzaC) on its own was able to reactivate H19. Combining AzaC treatment with HDAC inhibitors gave a reduced rather than enhanced reactivation. These findings were confirmed in mouse primary liver and kidney explants which maintain normal imprinting, where we also found that the silent Igf2 gene could not be reactivated by HDAC inhibitors.
        
        
          Conclusion
          These results suggest that DNA methylation rather than histone acetylation is the primary determinant of silencing of H19 in rhabdomyosarcoma.